Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
BANGALORE, India, June 23, 2011 /PRNewswire/ --
Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area.
The collaboration, initiated two years ago in the Neuroscience therapeutic area, has now expanded to Cardiovascular and Metabolic diseases and focuses on the delivery of a steady stream of preclinical outcomes to AstraZeneca, by Jubilant. AstraZeneca owns the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant derives research funding and success-based development and commercialization milestones.
Commenting on this development,Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant said: "We are pleased that we have delivered outcomes and early success to the portfolio efforts at AstraZeneca. This is the result of excellent collaboration between scientists at Jubilant and AstraZeneca.
"Partnering is a strategic priority for AstraZeneca at all stages of drug discovery and development," says Christof Angst, CNS & Pain Innovative Medicines, Vice-President, Strategy and Externalisation. "By combining our strengths with those of our partners, we are in a better position to deliver new medicines that can make a meaningful difference to patients' lives."
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.